Forsteo ® (teriparatide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Forsteo Summary of Product Characteristics (SmPC)

Forsteo® (teriparatide): Pregnancy During Treatment

Forsteo is contraindicated for use in women who are pregnant. If pregnancy occurs, Forsteo should be discontinued.

Information from Summary of Product Characteristics

Forsteo is contraindicated for use during pregnancy.1

Women of childbearing potential should use effective methods of contraception during use of Forsteo. If pregnancy occurs, Forsteo should be discontinued.1

Clinical Data in Humans

The effect of teriparatide on human fetal development has not been studied and the potential risk for humans is unknown.

Data from Studies in Animals

Teriparatide was not genotoxic in a standard battery of tests. It produced no teratogenic effects in rats, mice or rabbits. There were no important effects observed in pregnant rats or mice administered teriparatide at daily doses of 30 to 1000 µg/kg. However, fetal resorption and reduced litter size occurred in pregnant rabbits administered daily doses of 3 to 100 µg/kg. The embryotoxicity observed in rabbits may be related to their much greater sensitivity to the effects of PTH on blood ionised calcium compared with rodents.1

References

1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: February 05, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question